FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Three years ago it joined forces with Bristol-Myers Squib b to test it alongside BMS’PD-1 inhibitor Opdivo (nivolumab) in solid tumours, and has also looked into pairing the

Cancer immunotherapy: What's on the horizon?

Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have

Mallinckrodt doses first patient in muscular dystrophy trial

Other therapeutic approaches under test for DMD include gene-editing with CRISPR/Cas9, myostatin inhibitors from Pfizer, Bristol-Myers Squibb and Biogen/AliveGen, and Santhera’s antioxidant idebenone, which like

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)